Delving into the Latest Updates on Gannan Medical University with Synapse

Overview

Tags

Neoplasms

Endocrinology and Metabolic Disease

Digestive System Disorders

Small molecule drug

Antibody drug conjugate (ADC)

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	4
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Small molecule drug	3
Antibody drug conjugate (ADC)	1

Top 5 Target	Count

HDAC3(Histone deacetylase 3)	2
DR5 x Tubulin	1
HDAC6 x PDL1	1

Skin cutaneous melanoma (SKCM) is an aggressive tumor with a poor prognosis. We developed SKCM-P8, a novel qualitative prognostic biomarker based on the relative methylation orderings of eight pairs of loci. Analysis of a training cohort and two independent validation datasets revealed a significant difference in overall survival between high- and low-risk groups stratified by SKCM-P8 (p < 0.05, log-rank test), with average area under the curve values of 0.83, 0.80, and 0.61, respectively. The differential methylation loci between high- and low-risk patients were enriched in immune-related biological processes and signaling pathways. Furthermore, low-risk patients exhibited higher CD8+ T cells and B levels, while high-risk patients had higher monocytes. The methylation levels of SKCM-P8 were also correlated with immune cell levels, indicating that they can reflect prognosis-related immune information. The low-risk group had a significantly higher mutation burden (p < 0.05, Wilcoxon test), suggesting potential benefits from immune checkpoint inhibitors. Patients stratified by SKCM-P8 displayed differential responses to therapy and immunotherapy (p < 0.05, Wilcoxon test), with low-risk patients showing better sensitivity and response. Furthermore, SKCM-P8 demonstrated super-predictive accuracy compared to six published models. Overall, SKCM-P8 offers a promising tool for predicting prognosis and guiding therapeutic decisions in SKCM.

01 Jul 2025·European Journal of Medicinal Chemistry

Design, synthesis and bioevaluation of novel hydrazide derivatives as enhancers of immunotherapy and DNA-damage response in antitumor therapy

Article

Author: Li, Shuqing ; Peng, Xiaopeng ; Pan, Wanyi ; Hu, Zhihao ; Wu, Haiyan

We have designed and synthesized a series of novel hydrazide-based HDAC3 inhibitors, with the representative compound 8ae demonstrating potent HDAC3 inhibitory activity, having an IC₅₀ value of 311 nM (with a selectivity index SI greater than 32 over other HDACs). Compound 8ae also exhibited significant anti-proliferative activity against five types of cancer cells, with an average inhibitory rate IC₅₀ value of 5.036 μM, and was capable of inhibiting the migration, invasion, and wound healing activities of B16-F10 cells. Further studies revealed that 8ae effectively modulates the expression of Ac-H3 within tumor cells and can degrade PD-L1 in tumor cells through the lysosome pathway mediated by cathepsin B (CTSB). Notably, 8ae also possesses favorable pharmacokinetic properties. In in vivo experiments, the combination of 8ae with the PD-L1 inhibitor NP-19 activated the immune system in melanoma-bearing mice, leading to an enhanced anti-tumor immune response (TGI = 65 %). When combined with olaparib, 8ae significantly enhanced tumor suppressive activity (TGI = 88 %) in a breast cancer mouse model and displayed a favorable safety profile. Collectively, 8ae is a promising HDAC3 inhibitor that warrants further exploration in cancer therapeutic strategies.

01 Jul 2025·The Journal of nutrition, health and aging

Association of life’s essential 8 with leukocyte telomere length and mitochondrial DNA copy number: Findings from the population-based UK Biobank study

Article

Author: Lin, Lijin ; Kong, Shuang ; Li, Jian ; Mao, Li ; Lei, Fang ; He, Jinxing ; Wang, Guoying ; Tian, Yu

OBJECTIVESTo explore the association of Life's Essential 8 (LE8) levels with leukocyte telomere length (LTL) and mitochondrial DNA copy number (mtDNA-CN).DESIGNA cross-sectional study.SETTING AND PARTICIPANTS225,692 participants aged 37-73 year from the UK Biobank cohort enrolled from 2006 to 2010.MEASUREMENTSThe LE8 score (0-100) was divided into low (<50), moderate (50-79), and high cardiovascular health (CVH) (≥80) categories, based on health behaviors and factors defined by the American Heart Association. LTL was measured by a validated quantitative polymerase chain reaction method. mtDNA-CN was reacted by standardized SNP probe intensities. The association of CVH (as both a continuous and categorical variable) with LTL and mtDNA-CN was examined using multiple linear regression.RESULTSOf 225,692 participants, 5.3% had low CVH, 81.2% had moderate CVH, and 13.4% had high CVH. Participants with higher CVH were usually younger, female, better educated, of higher socioeconomic status, and with a lower prevalence of comorbidities. After adjusting for confounders, a higher LE8 score is associated with longer LTL (Beta = 0.075, P < 0.05) and increased mtDNA-CN (Beta = 0.094, P < 0.05). We also observed that this association was evident in the health behavior score (diet, physical activity, nicotine exposure, and sleep) and the health factors score (BMI, non-HDL cholesterol, blood glucose, and blood pressure), with a stronger positive association of health factors with LTL and mtDNA-CN (Beta = 0.019, P < 0.05; Beta = 0.037, P < 0.05).CONCLUSIONSHigher CVH is associated with longer LTL and increased mtDNA-CN.

100 Deals associated with Gannan Medical University

Login to view more data

100 Translational Medicine associated with Gannan Medical University

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 09 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

2

Preclinical

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

LSQ-28 ( HDAC3 )	Neoplasms More	Preclinical
Oba-01 ( DR5 x Tubulin )	Pancreatic Cancer More	Preclinical
PD-L1/HDAC6 dual inhibitors(Gannan Medical University) ( HDAC6 x PDL1 )	Neoplasms More	Discovery
HQ-30 ( HDAC3 )	Neoplasms More	Discovery